Loading…

Genus plcGNS.LCompetitor analysis, valuation and peers

United Kingdom · GBP·Consumer Staples›Agricultural Commodities/Milling

UK animal-genetics company breeding and selling superior pig (PIC) and cattle (ABS) breeding stock.

≈ A UK genetics-focused livestock supplierMomentum weak 24
Mkt cap
$1.81B
US dollars, full cap
Free float
95%
of shares outstanding
$/day
$5.39M
20-day average traded
Fwd P/E
21.2×
forward earnings
ROIC−WACC
-4.3 pp
WACC 12.2%
Hurdle
+13 pp
Req g minus delivered
Next earnings
99 days
25 Feb 2027
Close · GBP£2,156
1D-4.5%
1W-9.8%
1M-3.1%
3M-6.2%
6M-13.0%
YTD-16.9%
1Y-9.2%
ATR %3.9%
52w lowhigh33.0% off high

What Genus does

UK animal-genetics company breeding and selling superior pig (PIC) and cattle (ABS) breeding stock.

PIC is paid in part through royalties on the pigs its customers produce from its breeding stock, which ties income to herd size and pork production, while ABS sells bull semen to dairy and beef farmers. A gene-edited pig resistant to the PRRS virus, a major swine disease, is in development and needs approvals in export markets.

In one line: A UK genetics-focused livestock supplier.

Products and services

  • PIC pig genetics
  • ABS Global cattle/dairy genetics
  • Genomics/R&D services

Customers

  • Pig & dairy/beef farmers globally
  • Meat & dairy producers

Where it sits in the supply chain

  • Agriculture/Biotech
  • Animal genetics
  • Pig & cattle breeding stock/semen

What could go right

  • Global protein demand growth
  • Genetic-gain adoption in emerging markets

What could go wrong

  • Livestock disease outbreaks (e.g., swine fever)
  • Regulatory hurdles for gene editing

Moat: wide (IP / patents, scale, installed base). Decades of proprietary genetic-selection data give a hard-to-replicate breeding lead.

Headquarters: Basingstoke, UK · Founded: 1996 · Employees: 3,054

Named competitors

  • Topigs Norsvin private or unlisted
  • CRV private or unlisted
  • Semex private or unlisted

Genus at a glance

Size Genus (GNS.L) is a United Kingdom Consumer Staples company (Agricultural Commodities/Milling) with a market value of $1.81B, the 166th largest of 355 United Kingdom companies the cockpit tracks. Shares closed at £2,156 on 18 Nov 2026.

Performance Over six months the shares fell 13.0%, against +1.3% for the median peer and +0.1% for the United Kingdom market (cap-weighted) — 10th lowest of 20 in its peer set.

Growth Revenue fell 2.2% over the last twelve months (peer median +4.3%); the operating margin is 13.3% (peer median 7.4%).

Valuation It trades at 21.2× forward earnings against a peer median of 15.8× (5th most expensive of 15).

Price implies For today's price to make sense, revenue must grow about 16% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +13 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 4.3 points below its cost of capital (12.2% WACC).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 102GNS.L 88
Six months, rebased to 100: Genus against the median of its 20 peers (local-currency closes).

Genus financials

Reported figures in GBP; fiscal year ends 2026-06-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
Revenue£658M£658M£673M£669M£690M
Revenue growth—-2%+1%-3%—
Gross profit£617M£223M£207M£192M£247M
EBITDA£128M£123M£114M£103M£104M
Net income£285M£285M£19.3M£7.90M£33.3M
Free cash flow£78.0M£78.0M£59.9M£19.7M£27.1M
Capital expenditure£18.1M£18.1M£18.6M£24.7M£35.2M
Total debtn/a£108M£266M£291M£232M

Quarterly statements and history in the cockpit →

Genus competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%002385BIOMARUIETRLV002100000833000998601952P8ZCURALTFOODS11171229BFG002458BALRAMCHINKER2607GNS.L6-month return →1-month return →
Up and to the right = strong over both horizons. Genus is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%0×25×50×75×BIOMARTRLV000833000998601952P8ZLTFOODS000061BFG002458KERGNS.LRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Genus is the large dot.

Capital: growth delivered against growth the price implies

-20%-10%0%+10%+20%-20%0%20%BIOMARUIETRLV000833601952P8ZLTFOODS0000611229002458KER2607GNS.LGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Genus is the large dot.

Genus competitors and peer comparison

How Genus compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Genus against its 20 peers (data as of 18 Nov 2026)
MeasureGNS.LPeer medianRank in peer set
1-month return-3.1%-4.3%8th highest of 21
6-month return-13.0%+1.3%10th lowest of 20
Distance from 52-week high-33.0%-26.9%9th lowest of 21
Revenue growth (TTM)-2.2%+4.3%6th lowest of 21
Operating margin13.3%7.4%7th highest of 21
Forward P/E21.2×15.8×5th most expensive of 15
Growth the price implies (Req g, 7 yrs)16.1%1.9%2nd most demanding of 13
Growth delivered (Del g)+2.8%+12.0%4th lowest of 13
Hurdle (Req g minus delivered)+13.3 pp-5.9 pp2nd most demanding of 13
ROIC minus cost of capital-4.3 pp-1.6 pp7th lowest of 21
EV / EBITDA11.3×11.1×6th cheapest of 11
Net debt / EBITDA0.5×1.7×3rd least indebted of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Genus GNS.LUnited Kingdom$1.81B-13%-2%13%21.2×16.1%+2.8%
Beijing Dbn Technology 002385.SZChina$1.78B-22%-1%-6%n/an/an/a
BioMar Group A/S BIOMAR.CODenmark$1.85B-31%0%6%13.6×-1.2%-0.5%
Uie UIE.CODenmark$1.71B+8%+11%40%n/a-15.2%+13.1%
Trulieve Cannabis TRLVUnited States$1.93B+25%-9%15%28.5×11.2%+17.8%
Tecon Biology 002100.SZChina$1.69B+14%-8%-5%n/an/an/a
Guangxi Yuegui Guangye 000833.SZChina$1.96B-46%+67%30%8.6×0.4%-0.9%
Yuan Longping High-Tech Agriculture 000998.SZChina$1.65B-14%-5%5%43.5×n/an/a
Jiangsu Provincial Agricultural Reclamation & Dev 601952.SSChina$1.63B-13%-5%4%19.0×-2.9%+3.2%
Bumitama Agri P8Z.SISingapore$1.61B-28%+9%25%8.9×-16.8%+12.9%
Curaleaf CURA.TOCanada$2.10B-17%+5%1%n/an/an/a
LT Foods LTFOODS.NSIndia$1.56B+2%+24%8%12.8×25.8%+18.2%
Shenzhen Agricultural Products 000061.SZChina$1.52B-22%-22%12%24.4×3.5%+15.6%
China Modern Dairy 1117.HKHong Kong$1.50B+29%+5%-15%13.7×n/an/a
Lien Hwa Industrial 1229.TWTaiwan$2.20B+2%+1%19%n/a12.0%+7.3%
Liuliumei 6658.HKHong Kong$1.46Bn/a+6%12%n/an/an/a
B.F BFG.MIItaly$2.26B+59%+30%-2%85.0×n/an/a
Shandong Yisheng Livestock & Poultry Breeding 002458.SZChina$1.44B-25%+15%17%17.2×5.4%+11.1%
Balrampur Chini Mills BALRAMCHIN.NSIndia$1.44B+16%+11%9%18.7×n/an/a
Kernel KER.WAPoland$1.43B+1%-1%5%5.3×8.1%-5.4%
Fuji Oil 2607.TJapan$2.30B+24%+4%5%14.4×0.4%+16.2%

Questions

Who are Genus's main competitors?
Named competitors: Topigs Norsvin (private or unlisted), CRV (private or unlisted), Semex (private or unlisted). The cockpit's measured peer set (industry) also includes Beijing Dbn Technology (002385.SZ), BioMar Group A/S (BIOMAR.CO), Uie (UIE.CO), Trulieve Cannabis (TRLV), Tecon Biology (002100.SZ), Guangxi Yuegui Guangye (000833.SZ).
Is Genus expensive compared with its peers?
On forward p/e it trades at 21.2× against a peer median of 15.8×, 5th most expensive of 15 in its peer set. For today's price to make sense, revenue must grow about 16% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +13 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Genus stock performed?
Over six months to 18 Nov 2026 the shares returned -13.0% against +1.3% for the median peer; over one year -9.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.